Genedrive PLC (GB:GDR)
LSE:GDR
Want to see GB:GDR full AI Analyst Report?
GDR Stock Chart & Stats
0.88 p
0.03 p(1.30%)
At close: 4:00 PM EST
0.88 p
0.03 p(1.30%)
Day’s Range― - ―
52-Week Range0.19 p - 1.85 p
Previous CloseN/A
Volume280.42K
Average Volume (3M)49.58M
Market Cap
£17.26M
Enterprise Value6.57M
Total Cash (Recent Filing)£387.00K
Total Debt (Recent Filing)£500.00K
Price to Earnings (P/E)―
Beta-0.56
Next Earnings
Nov 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueGenedrive's business model sells capital instruments and single-use test kits, creating a built-in recurring revenue stream from consumables and service. An installed base that drives repeat cartridge purchases supports durable revenue visibility and margin leverage as volume scales.
Low Leverage And Minimal DebtThe company's negligible debt position reduces near-term financing and interest risk, preserving strategic flexibility. Low leverage lowers insolvency risk and gives management options to raise growth capital or invest in commercialization without immediate interest burdens.
Accelerating Revenue GrowthA 25% revenue increase in 2025 indicates improving market adoption of the Genedrive platform off a small base. If sustained, this growth can widen the installed base, increase recurring consumable sales, and create operating leverage that helps narrow structural losses over the medium term.
Bears Say
Sustained Negative Free Cash FlowPersistent negative operating and free cash flows imply the business cannot self-fund growth and remains dependent on external financing. Continued cash burn raises the risk of dilution, constrains long-term investment in commercial scale-up, and limits resilience to adverse shocks.
Deep Negative ProfitabilityLosses at the EBIT and net levels signal that the current cost structure outpaces revenue. Without material margin improvement or accelerated scale, sustained unprofitability undermines the durability of the business model and necessitates ongoing external funding to reach break-even.
Compressed Shareholders' EquityA sharply reduced equity base weakens the balance sheet cushion and increases vulnerability to further losses. Limited equity heightens the probability of future dilution during funding rounds and reduces capacity to invest or absorb setbacks without external capital.
Genedrive News
GDR FAQ
What was Genedrive PLC’s price range in the past 12 months?
Genedrive PLC lowest share price was 0.19 p and its highest was 1.85 p in the past 12 months.
What is Genedrive PLC’s market cap?
Genedrive PLC’s market cap is £17.26M.
When is Genedrive PLC’s upcoming earnings report date?
Genedrive PLC’s upcoming earnings report date is Nov 24, 2026 which is in 188 days.
How were Genedrive PLC’s earnings last quarter?
Genedrive PLC released its earnings results on Mar 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Genedrive PLC overvalued?
According to Wall Street analysts Genedrive PLC’s price is currently Overvalued.
Does Genedrive PLC pay dividends?
Genedrive PLC does not currently pay dividends.
What is Genedrive PLC’s EPS estimate?
Genedrive PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genedrive PLC have?
Genedrive PLC has 1,605,568,200 shares outstanding.
What happened to Genedrive PLC’s price movement after its last earnings report?
Genedrive PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Genedrive PLC?
Currently, no hedge funds are holding shares in GB:GDR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genedrive PLC
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Renalytix
―
Abingdon Health PLC
―
Aptamer Group Plc
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---